Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MCRB
stocks logo

MCRB

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
4 Analyst Rating
up Image0
Wall Street analysts forecast MCRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCRB is 13.33 USD with a low forecast of 6.00 USD and a high forecast of 20.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
2 Hold
0 Sell
Moderate Buy
up Image0
Current: 7.500
sliders
Low
6.00
Averages
13.33
High
20.00
up Image0
Current: 7.500
sliders
Low
6.00
Averages
13.33
High
20.00
Chardan Capital
Keay Nakae
Strong Buy
to
Hold
Downgrades
$1.25 → $6
2025-05-08
Reason
Chardan Capital
Keay Nakae
Price Target
$1.25 → $6
2025-05-08
Downgrades
Strong Buy
to
Hold
Reason
Chardan Capital
Keay Nakae
Strong Buy
Maintains
$1.25
2025-03-20
Reason
Chardan Capital
Keay Nakae
Price Target
$1.25
2025-03-20
Maintains
Strong Buy
Reason
Goldman Sachs
Chris Shibutani
Strong Sell
Maintains
$1 → $0.75
2025-03-14
Reason
Goldman Sachs
Chris Shibutani
Price Target
$1 → $0.75
2025-03-14
Maintains
Strong Sell
Reason
Canaccord Genuity
John Newman
Strong Buy
Maintains
$10
2024-11-14
Reason
Canaccord Genuity
John Newman
Price Target
$10
2024-11-14
Maintains
Strong Buy
Reason
Chardan Capital
Keay Nakae
Strong Buy
Maintains
$1.25
2024-11-13
Reason
Chardan Capital
Keay Nakae
Price Target
$1.25
2024-11-13
Maintains
Strong Buy
Reason
JP Morgan
Tessa Romero
Hold
to
Sell
Downgrades
n/a
2024-10-24
Reason
JP Morgan
Tessa Romero
Price Target
n/a
2024-10-24
Downgrades
Hold
to
Sell
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Seres Therapeutics Inc (MCRB.O) is -1.09, compared to its 5-year average forward P/E of -7.28. For a more detailed relative valuation and DCF analysis to assess Seres Therapeutics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.28
Current PE
-1.09
Overvalued PE
8.04
Undervalued PE
-22.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7.35
Current EV/EBITDA
-1.00
Overvalued EV/EBITDA
12.01
Undervalued EV/EBITDA
-26.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
26.16
Current PS
12.23
Overvalued PS
55.79
Undervalued PS
-3.47

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

MCRB News & Events

Events Timeline

(ET)
2025-05-27
07:16:51
Seres Therapeutics presents expanded SER-155 biomarker data at ASCO meeting
select
2025-05-07 (ET)
2025-05-07
07:01:41
Seres Therapeutics reports Q1 EPS $3.75, consensus $1.97
select
2025-04-29 (ET)
2025-04-29
07:17:31
Seres Therapeutics presents three posters at DDW Conference
select
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
05-08Benzinga
This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

  • Analyst Downgrades: Several Wall Street analysts have downgraded their ratings on stocks including Seres Therapeutics, Coty Inc, Axalta Coating Systems, and Theriva Biologics, with adjustments in price targets reflecting varying outlooks on these companies.

  • Market Reactions: The downgrades have led to notable changes in stock prices, with Seres Therapeutics closing at $8.29, Coty at $4.57, Axalta at $31.69, and Theriva Biologics at $0.81, indicating mixed investor sentiment following the analysts' revisions.

Preview
4.0
05-08Benzinga
Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday

  • Analyst Rating Changes: Several Wall Street analysts have adjusted their price targets and ratings for various companies, including raising targets for Coherent Corp and Uber Technologies, while cutting targets for Genpact Limited and Holley Inc.

  • Stock Performance: The article highlights the closing prices of affected stocks, with notable movements such as Seres Therapeutics trading at $8.29 and Unity Software at $20.66, reflecting the impact of analyst updates on market perceptions.

Preview
9.5
04-22Benzinga
Quest Diagnostics Posts Better-Than-Expected Earnings, Joins Pentair, 3M, Danaher And Other Big Stocks Moving Higher On Tuesday

  • U.S. Stock Market Performance: U.S. stocks rose significantly, with the Dow Jones gaining around 600 points on Tuesday, driven by strong earnings reports from companies like Quest Diagnostics and others.

  • Notable Stock Gains: Quest Diagnostics shares surged 7.3% after beating earnings expectations, while other companies such as PureCycle Technologies, Hesai Group, and Equifax also saw substantial increases in their stock prices following positive financial results or announcements.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Seres Therapeutics Inc (MCRB) stock price today?

The current price of MCRB is 7.5 USD — it has decreased -6.13 % in the last trading day.

arrow icon

What is Seres Therapeutics Inc (MCRB)'s business?

Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.

arrow icon

What is the price predicton of MCRB Stock?

Wall Street analysts forecast MCRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCRB is 13.33 USD with a low forecast of 6.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Seres Therapeutics Inc (MCRB)'s revenue for the last quarter?

Seres Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Seres Therapeutics Inc (MCRB)'s earnings per share (EPS) for the last quarter?

Seres Therapeutics Inc. EPS for the last quarter amounts to 75.00 USD, decreased -1466.12 % YoY.

arrow icon

What changes have occurred in the market's expectations for Seres Therapeutics Inc (MCRB)'s fundamentals?

The market is revising Downward the revenue expectations for Seres Therapeutics, Inc. (MCRB) for FY2025, with the revenue forecasts being adjusted by -80.32% over the past three months. During the same period, the stock price has changed by -49.18%.
arrow icon

How many employees does Seres Therapeutics Inc (MCRB). have?

Seres Therapeutics Inc (MCRB) has 103 emplpoyees as of June 16 2025.

arrow icon

What is Seres Therapeutics Inc (MCRB) market cap?

Today MCRB has the market capitalization of 65.49M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free